# Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

> **NCT03121001** · PHASE2 · RECRUITING · sponsor: **University of Illinois at Chicago** · enrollment: 50 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** ATG
- **DRUG:** fludarabine
- **DRUG:** cyclophosphamide
- **RADIATION:** Total body irradiation
- **PROCEDURE:** Stem cell infusion
- **DRUG:** Sirolimus
- **DRUG:** mycophenolate mofetil

## Key facts

- **NCT ID:** NCT03121001
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-03-20
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03121001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03121001, "Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03121001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*